OTCMKTS:OTLC Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis $0.02 0.00 (0.00%) As of 09/18/2026 03:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Oncotelic Therapeutics Stock (OTCMKTS:OTLC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oncotelic Therapeutics alerts:Sign Up Key Stats Today's Range$0.02▼$0.0350-Day Range$0.02▼$0.0552-Week Range$0.02▼$0.11Volume163,250 shsAverage Volume254,507 shsMarket Capitalization$10.68 millionP/E Ratio0.04Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oncotelic Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer and other serious diseases. The company’s research platform emphasizes RNA-based therapeutics and targets biological pathways involved in tumor growth, immune response, and disease progression. Its principal investigational product is OT-101, also known as trabedersen, an antisense oligonucleotide designed to inhibit transforming growth factor beta 2 (TGF-β2). Oncotelic has studied OT-101 in several oncology settings, including brain and other solid tumors. The company has also explored additional therapeutic programs in areas such as infectious disease and rare disorders, although its pipeline and development priorities may change over time. Oncotelic was formed through the combination of businesses associated with Oncotelic and Mateon Therapeutics and is led by Chief Executive Officer Vuong Trieu. The company conducts research and development through collaborations and clinical activities intended to support the advancement of its investigational medicines. Its products remain in development and are not broadly marketed commercial therapies.AI Generated. May Contain Errors. Read More Receive OTLC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OTLC Stock News HeadlinesOncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6thAugust 3, 2026 | financialpost.comFOncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6thAugust 3, 2026 | globenewswire.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under. | Paradigm Press (Ad)Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)July 22, 2026 | globenewswire.comOTLC Share News TodayJuly 14, 2026 | uk.investing.comOncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion UnderwayJuly 7, 2026 | globenewswire.comOncotelic Therapeutics Enters New Convertible Note FinancingJune 29, 2026 | tipranks.comOncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003June 29, 2026 | globenewswire.comSee More Headlines OTLC Stock Analysis - Frequently Asked Questions How have OTLC shares performed this year? Oncotelic Therapeutics' stock was trading at $0.0775 at the beginning of the year. Since then, OTLC shares have decreased by 69.8% and is now trading at $0.0234. How were Oncotelic Therapeutics' earnings last quarter? Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) issued its quarterly earnings results on Wednesday, April, 15th. The company reported $0.59 earnings per share for the quarter. How do I buy shares of Oncotelic Therapeutics? Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncotelic Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncotelic Therapeutics investors own include MariMed (MRMD), DSS (DSS), Cemex (CX), CohBar (CWBR), Company Calendar Last Earnings4/15/2026Today9/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:OTLC CIK908259 Webwww.mateon.com Phone(650) 635-7000Fax650-635-7001Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.59 Trailing P/E Ratio0.04 Forward P/E RatioN/A P/E GrowthN/ANet Income$249.28 million Net MarginsN/A Pretax Margin143,532.39% Return on Equity123.75% Return on Assets81.36% Debt Debt-to-Equity Ratio0.01 Current Ratio0.08 Quick Ratio0.08 Sales & Book Value Annual Sales$70 thousand Price / Sales152.60 Cash Flow$0.59 per share Price / Cash Flow0.04 Book Value$0.59 per share Price / Book0.04Miscellaneous Outstanding Shares456,490,000Free Float277,456,000Market Cap$10.68 million OptionableNot Optionable Beta-0.24 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:OTLC) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncotelic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncotelic Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
